Literature DB >> 30635235

Combined heart and liver transplantation: State of knowledge and outlooks.

Pascal Lebray1, Shaida Varnous2.   

Abstract

Various types of liver impairment have been described in patients with end-stage heart failure who are awaiting heart transplantation. The liver impairment may be severe, characterized by a high model for end-stage liver disease (MELD) Score and/or the presence of ascites, both of which are associated with a high risk of failure after single heart transplantation. A liver function assessment is therefore necessary before registration on the heart transplant list, moreover in case of long-developing heart failure, such as with congenital heart disease or in the presence of risk factors for chronic liver disease including excessive alcohol consumption, metabolic syndrome or chronic viral hepatitis B or C. In these instances, screening for cirrhosis with liver biopsy and for hepatocellular carcinoma through imaging must be systematic and when present, the indication for combined heart-liver transplantation must be considered. Its benefits, however, in case of liver failure with a high MELD score or multi-organ failure remains to be demonstrated. An exception in which the liver shows no morphological or functional alteration is with familial amyloid neuropathy, during which moderate to severe heart failure implies surgical treatment consisting of a liver or even heart-liver transplantation. These must be done early and are mainly contraindicated according to the level of neurological damage.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Combined heart-liver transplantation; Familial amyloid neuropathy; Fontan procedure; MELD; Survival

Mesh:

Year:  2019        PMID: 30635235     DOI: 10.1016/j.clinre.2018.08.009

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  4 in total

Review 1.  From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?

Authors:  Anna Sessa; Manon Allaire; Pascal Lebray; Mourad Medmoun; Alberto Tiritilli; Pierre Iaria; Jean-François Cadranel
Journal:  JHEP Rep       Date:  2021-01-27

2.  Levels of serum IgG subclasses in patients with liver disease: A retrospective study.

Authors:  Wei Zheng; Feifei Jiang; Jing Shan; Ying Wang; Yongmei Jia; Qiuyan Guo; Jinli Lou; Yan Zhao
Journal:  Exp Ther Med       Date:  2020-11-17       Impact factor: 2.447

Review 3.  Congestive Hepatopathy.

Authors:  José Ignacio Fortea; Ángela Puente; Antonio Cuadrado; Patricia Huelin; Raúl Pellón; Francisco José González Sánchez; Marta Mayorga; María Luisa Cagigal; Inés García Carrera; Marina Cobreros; Javier Crespo; Emilio Fábrega
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

4.  Anesthesia management of combined sequential heart-liver transplantation using a caval clamp without venovenous bypass: A case report.

Authors:  Ye-Ke Zhu; Yan-Feng Zhou; Tian-Xiang Zhang; Yong-Xing Yao
Journal:  Heliyon       Date:  2022-09-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.